| abstract |
FIELD: pharmaceutics. n SUBSTANCE: present invention relates to novel piperidine compound of general formula (I) or its pharmaceutically acceptable salt. Besides, present invention relates to novel agent for enhancing anti-tumour effect, agonist, which include taxane anticancer agent for combined therapy. In compounds of formula (I) R 1 is carboxyl group of -C(=O)NR 5 R 6 or oxadiazolyl group, optionally containing C 1 -C 6 alkyl group or trifluoromethyl group as substitute; R 2 is halogen atom or C 1 -C 6 alkoxy group; R 3 is phenyl group, optionally containing 1-3 identical or different groups selected from halogen atom, C 1 -C 6 alkyl group C 1 -C 6 alkoxy group and trifluoromethyl group as substitute; R 4 is a hydrogen atom or C 1 -C 6 alkyl group; and R 5 and 6 are identical or different, and each denotes a hydrogen atom, C 1 -C 6 alkyl group or C 3 -C 6 cycloalkyl group, or R 5 and R 6 optionally form 3-6-member nitrogen containing heterocyclic group saturated together with nitrogen atom to which R 5 and R 6 are connected. n EFFECT: this compound has excellent aurora A selective inhibiting action and is suitable as orally administered anticancer drug. n 24 cl, 23 tbl, 28 ex |